Thursday, October 22, 2020

Design Therapeutics Appoints Industry Veteran, Dr. João Siffert, as Chief Executive Officer

Design Therapeutics. San Diego, Calif., Oct. 20, 2020

Design Therapeutics, a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of serious degenerative disorders caused by nucleotide repeat expansions, today announced that João Siffert, M.D., has been appointed as chief executive officer and will also join the Board of Directors. Dr. Siffert joins the founding Design Therapeutics team, including Pratik Shah, Ph.D., co-founder and executive chairman; Aseem Ansari, Ph.D., co-founder and director; and Sean Jeffries, Ph.D., chief business officer. Dr. Siffert brings extensive industry knowledge to Design, with 30 years combined experience in the biopharmaceutical industry, clinical practice and academia. 

 Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on the treatment of Friedreich ataxia and discovery efforts are ongoing in other for serious degenerative disorders caused by nucleotide repeat expansions.